Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN PEDIATRIC versus NALLPEN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN PEDIATRIC versus NALLPEN IN PLASTIC CONTAINER.
AMOXICILLIN PEDIATRIC vs NALLPEN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). It blocks the transpeptidation step in peptidoglycan cross-linking, leading to cell lysis and death.
Nallpen is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically active against beta-lactamase-producing Staphylococcus aureus.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours for adults.
Nafcillin 1-2 g IV every 4 hours for moderate to severe infections; for MSSA bacteremia or endocarditis, 2 g IV every 4 hours.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in children with normal renal function; prolonged to 7-21 hours in anuria.
0.9-1.2 hours; prolonged in renal impairment (up to 7-10 hours in anuria); requires dose adjustment for CrCl <30 mL/min
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; biliary: minor (<10%); fecal: <5%.
Primarily renal (60-80% unchanged drug via glomerular filtration and tubular secretion); biliary/fecal: minor (<5%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic